Skip to main content

onc201

Generic: dordaviprone·Code: ONC201

onc201: sourced relationships with 1 company · 4 clinical trials tracked.

onc201 evidence translation

What we can confirm

4 tracked trials

What it means

Source-backed records connect onc201 to CMRX; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could onc201 → CMRX affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 0 study sponsors

Related indications

H3 K27M-mutant gliomaDiffuse Intrinsic Pontine GliomaEndometrial CancerMeningioma

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
CHIMERIX INC (CMRX)
developer · Reported 2023-03-02 · Current development: unknownSource
H3 K27M-mutant glioma
Phase 3
Clinical Trial Registry Records (4)

A Pilot Study, Open-Label Study of ONC201 for Refractory Meningioma

NCT06012929Registry updated 2026-01-26·Phase 2
Withdrawn

Primary endpoint: Evaluation of ONC201 concentration in resected meningioma tissue

Interventionalopen0 targetStarted 2026-12Completion 2027-04University of Nebraska

Phase 1 Clinical Trial of ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer

NCT05542407Registry updated 2026-01-29·Phase 1
Recruiting

Primary endpoint: Recommended phase 2 dose (RP2D)

Interventionalopen58 targetStarted 2023-10Completion 2028-071 site · United StatesUNC Lineberger Comprehensive Cancer Center

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication

NCT05476939Registry updated 2026-08-13·Phase 3
Recruiting

Primary endpoint: Progression-free survival

InterventionalRandomizedopen433 targetStarted 2022-09Completion 2031-0950 sites · Denmark, Finland, France, Norway…Gustave Roussy, Cancer Campus, Grand Paris

A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression

NCT05009992Registry updated 2026-06-26·Phase 2
Recruiting

Primary endpoint: Progression-free survival at 6 months (PFS6) - Cohorts 1A, 1B Only

InterventionalRandomizedopen360 targetStarted 2021-10Completion 2029-0632 sites · Australia, Israel, Netherlands, New Zealand…University of California, San Francisco

Frequently asked questions

Which companies have sourced relationships with onc201?

onc201 has dated SEC/FDA relationship records for CHIMERIX INC.

How many clinical trials involve onc201?

BioSniper tracks 4 clinical trials involving onc201.